Moreover, in vivo efficacy often diverges from in vitro results, as with GBP1 in glioblastoma, requiring robust preclinical models (e.g., patient-derived xenografts, organoids) to bridge the gap, assessable through comparative efficacy trials [16,17]. This evidence concerns the gene GBP1 and glioblastoma.